| 1 |
31746285 | Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants. | 2021 Jan |
1 |
| 2 |
33674983 | Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). | 2021 Oct |
1 |
| 3 |
31793049 | Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment. | 2020 Apr |
2 |
| 4 |
31831187 | Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. | 2020 Feb |
2 |
| 5 |
31839722 | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. | 2020 Feb 15 |
2 |
| 6 |
31877292 | Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. | 2020 Aug |
1 |
| 7 |
32023227 | Effects of Rivaroxaban on Platelet Aggregation. | 2020 Feb |
1 |
| 8 |
31552542 | The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. | 2019 Dec |
1 |
| 9 |
31649541 | International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study. | 2019 |
3 |
| 10 |
31656515 | Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report. | 2019 Jun |
1 |
| 11 |
31731710 | Rivaroxaban Effects Illustrate the Underestimated Importance of Activated Platelets in Thrombin Generation Assessed by Calibrated Automated Thrombography. | 2019 Nov 15 |
1 |
| 12 |
31768290 | Rivaroxaban-induced acute cervical spine epidural hematoma: Report of a case and review. | 2019 |
1 |
| 13 |
31808849 | Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. | 2019 Dec 6 |
1 |